Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder

Neuropsychiatric Disease and Treatment

Volumn 13, Issue , 2017, Pages 803-813

  Jha, Manish K ^a   Teer, Raymond B ^b   Minhajuddin, Abu ^a   Greer, Tracy L ^a   Rush, A John ^c   Trivedi, Madhukar H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Activity impairment; Depression; Functional recovery; Predictors; Productivity

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ESCITALOPRAM; MIRTAZAPINE; PLACEBO; VENLAFAXINE;

ANHEDONIA; ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; EMPLOYMENT STATUS; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTPATIENT; PRODUCTIVITY; QUALITY OF LIFE; REMISSION; SCORING SYSTEM; SOCIAL PSYCHOLOGY; SUICIDAL IDEATION; TREATMENT OUTCOME;

EID: 85015808460     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S128407     Document Type: Article

References (48)

1. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the national epidemiologic survey on alcoholism and related conditions. Arch Gen Psychiatry. 2005; 62(10):1097–1106.
2. Kessler RC, Berglund P, Demler O, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder. JAMA. 2003;289(23):3095–3105.
3. Vos T, Barber RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995): 743–800.
4. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder third edition. Am J Psychiatry. 2010;167(10):1.
5. Trivedi MH, Morris DW, Wisniewski SR, et al. Increase in work productivity of depressed individuals with improvement in depressive symptom severity. Am J Psychiatry. 2013;170(6):633–641.
6. Beck A, Crain AL, Solberg LI, et al. Severity of depression and magnitude of productivity loss. Ann Fam Med. 2011;9(4):305–311.
7. Trivedi MH, Dunner DL, Kornstein SG, et al. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord. 2010;126(3):420–429.
8. Bech P. Social functioning: should it become an endpoint in trials of antidepressants? CNS Drugs. 2005;19(4):313–324.
9. Ishak WW, Christensen S, Sayer G, et al. Sexual satisfaction and quality of life in major depressive disorder before and after treatment with citalopram in the STAR*D study. J Clin Psychiatry. 2013;74(3):256–261.
10. Jha MK, Minhajuddin A, Thase ME, Jarrett RB. Improvement in self-reported quality of life with cognitive therapy for recurrent major depressive disorder. J Affect Disord. 2014;167:37–43.
11. Stein MB, Heimberg RG. Well-being and life satisfaction in generalized anxiety disorder: comparison to major depressive disorder in a community sample. J Affect Disord. 2004;79(1–3):161–166.
12. Quilty LC, Mainland BJ, McBride C, Bagby RM. Interpersonal problems and impacts: further evidence for the role of interpersonal functioning in treatment outcome in major depressive disorder. J Affect Disord. 2013;150(2):393–400.
13. Wells KB, Sherbourne CD. Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices. Arch Gen Psychiatry. 1999;56(10):897–904.
14. Hays RD, Wells KB, Sherbourne CD, Rogers W, Spritzer K. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry. 1995;52(1):11–19.
15. Cohen RM, Greenberg JM, IsHak WW. Incorporating multidimensional patient-reported outcomes of symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression to measure treatment impact and recovery in MDD. JAMA Psychiatry. 2013;70(3):343–350.
16. Jha MK, Greer TL, Grannemann BD, Carmody T, Rush AJ, Trivedi MH. Early normalization of quality of life predicts later remission in depression: findings from the CO-MED trial. J Affect Disord. 2016;206:17–22.
17. Jha MK, Minhajuddin A, Greer TL, Carmody T, Rush AJ, Trivedi MH. Early improvement in psychosocial function predicts longer-term symptomatic remission in depressed patients. PLoS One. 2016;11(12):e0167901.
18. Jha MK, Minhajuddin A, Greer TL, Carmody T, Rush AJ, Trivedi MH. Early improvement in work productivity predicts future clinical course in depressed outpatients: findings from the CO-MED trial. Am J Psychiatry. 2016;173(12):1196–1204.
19. Jakubovski E, Bloch MH. Prognostic subgroups for citalopram response in the STAR*D trial. J Clin Psychiatry. 2014;75(7):738–747.
20. Fujii RK, Goren A, Annunziata K, Mould-Quevedo J. Prevalence, awareness, treatment, and burden of major depressive disorder: estimates from the national health and wellness survey in Brazil. Value Health Regional Issues. 2012;1(2):235–243.
21. Gupta S, Goren A, Dong P, Liu D. Prevalence, awareness, and burden of major depressive disorder in urban China. Expert Rev Pharmacoecon Outcomes Res. 2016;16(3):393–407.
22. Lam RW, Endicott J, Hsu MA, Fayyad R, Guico-Pabia C, Boucher M. Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine. Int Clin Psychopharmacol. 2014;29(5):239–251.
23. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP task force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31(9):1841–1853.
24. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011; 168(7):689–701.
25. Vittengl JR, Clark LA, Jarrett RB. Improvement in social-interpersonal functioning after cognitive therapy for recurrent depression. Psychol Med. 2004;34(4):643–658.
26. Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40.
27. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004; 34(1):73–82.
28. Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA, STARD Investigators. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12(2):71–79.
29. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365.
30. Reilly MC [webpage on the Internet]. WPAI Scoring. Available from: http://www.reillyassociates.net/WPAI_Scoring.html. Accessed May 17, 2015.
31. Gupta S, Goren A, Phillips AL, Stewart M. Self-reported burden among caregivers of patients with multiple sclerosis. Int J MS Care. 2012;14(4): 179–187.
32. Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the quick inventory of depressive symptomatology and the Hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry. 2006;59(6):493–501.
33. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583.
34. Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002;180:461–464.
35. Zahra D, Qureshi A, Henley W, et al. The work and social adjustment scale: reliability, sensitivity and value. Int J Psychiatry Clin Pract. 2014; 18(2):131–138.
36. Frisch M. Quality-of-life-inventory. In: Michalos A, editor. Encyclopedia of Quality of Life and Well-Being Research. Netherlands: Springer; 2014:5374–5377.
37. McAlinden NM, Oei TP. Validation of the quality of life inventory for patients with anxiety and depression. Compr Psychiatry. 2006;47(4): 307–314.
38. Danovitch I, Endicott J. Quality of life measures. In: Rush AJ, First MB, Blacker D, editors. Handbook of Psychiatric Measures. Washington, DC, USA: American Psychiatric Publishing; 2008:125–140.
39. Fava M, Iosifescu DV, Pedrelli P, Baer L. Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. Psychother Psychosom. 2009;78(2):91–97.
40. Baer L, Ball S, Sparks J, et al. Further evidence for the reliability and validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ). Ann Clin Psychiatry. 2014;26(4): 270–280.
41. Schatzberg AF, DeBattista C, Lazzeroni LC, et al. ABCB1 genetic effects on antidepressant outcomes: a report from the iSPOT-D Trial. Am J Psychiatry. 2015;172(8):751–759.
42. Hamlett A, Ryan L, Wolfinger R. On the use of PROC MIXED to estimate correlation in the presence of repeated measures. Proc Statistics and Data Analysis SAS Users Group International. Vol. 19. 2006. Available from: http://www2.sas.com/proceedings/sugi29/198-29.pdf. Accessed November 11, 2016.
43. Bland JM, Altman DG. Statistics notes: correlation, regression, and repeated data. BMJ. 1994;308(6933):896.
44. Zimmerman M, Martinez JA, Attiullah N, et al. Why do some depressed outpatients who are in remission according to the Hamilton Depression Rating Scale not consider themselves to be in remission? J Clin Psychiatry. 2012;73(6):790–795.
45. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Attiullah N, Boerescu D. How should remission from depression be defined? The depressed patient’s perspective. Am J Psychiatry. 2006; 163(1):148–150.
46. Trivedi MH, Greer TL, Church TS, et al. Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. J Clin Psychiatry. 2011;72(5):677–684.
47. Fulcher KY, White PD. Randomised controlled trial of graded exercise in patients with the chronic fatigue syndrome. BMJ. 1997; 314(7095):1647.
48. Tench CM, McCarthy J, McCurdie I, White PD, D’Cruz DP. Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise. Rheumatology. 2003;42(9):1050–1054.